424 related articles for article (PubMed ID: 27165582)
21. MUC1, MUC2, MUC4, and MUC5AC expression in salivary gland mucoepidermoid carcinoma: diagnostic and prognostic implications.
Handra-Luca A; Lamas G; Bertrand JC; Fouret P
Am J Surg Pathol; 2005 Jul; 29(7):881-9. PubMed ID: 15958852
[TBL] [Abstract][Full Text] [Related]
22. Expression of MUC apomucins in normal pancreas and pancreatic tumours.
Terada T; Ohta T; Sasaki M; Nakanuma Y; Kim YS
J Pathol; 1996 Oct; 180(2):160-5. PubMed ID: 8976874
[TBL] [Abstract][Full Text] [Related]
23. Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in mucinous carcinoma of the breast: comparison with invasive ductal carcinoma.
Matsukita S; Nomoto M; Kitajima S; Tanaka S; Goto M; Irimura T; Kim YS; Sato E; Yonezawa S
Histopathology; 2003 Jan; 42(1):26-36. PubMed ID: 12493022
[TBL] [Abstract][Full Text] [Related]
24. Mucins and CD56 as markers of tumour invasion and prognosis in periampullary cancer.
Aloysius MM; Zaitoun AM; Awad S; Ilyas M; Rowlands BJ; Lobo DN
Br J Surg; 2010 Aug; 97(8):1269-78. PubMed ID: 20602499
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical study of the association between the progression of pancreatic ductal lesions and the expression of MUC1, MUC2, MUC5AC, and E-cadherin.
Kigure S
Rinsho Byori; 2006 May; 54(5):447-52. PubMed ID: 16789413
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic and therapeutic implications of a novel immunohistochemical panel detecting duodenal mucosal invasion by pancreatic ductal adenocarcinoma.
Sopha SC; Gopal P; Merchant NB; Revetta FL; Gold DV; Washington K; Shi C
Int J Clin Exp Pathol; 2013; 6(11):2476-86. PubMed ID: 24228110
[TBL] [Abstract][Full Text] [Related]
27. MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance.
Betge J; Schneider NI; Harbaum L; Pollheimer MJ; Lindtner RA; Kornprat P; Ebert MP; Langner C
Virchows Arch; 2016 Sep; 469(3):255-65. PubMed ID: 27298226
[TBL] [Abstract][Full Text] [Related]
28. Significance of mucin expression in pancreatobiliary neoplasms.
Yonezawa S; Higashi M; Yamada N; Yokoyama S; Goto M
J Hepatobiliary Pancreat Sci; 2010 Mar; 17(2):108-24. PubMed ID: 19787286
[TBL] [Abstract][Full Text] [Related]
29. Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma.
Qian Y; Gong Y; Liu Y; Chen Y; Wang R; Dai Z; Zou X; Tasiheng Y; Luo G; Lin X; Wang X; Cheng H; Yu X; Liu C
J Immunol Res; 2022; 2022():7353572. PubMed ID: 35910854
[TBL] [Abstract][Full Text] [Related]
30. Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers.
Duruisseaux M; Antoine M; Rabbe N; Rodenas A; Mc Leer-Florin A; Lacave R; Poulot V; Duchêne B; Van Seuningen I; Cadranel J; Wislez M
Lung Cancer; 2017 Jul; 109():92-100. PubMed ID: 28577958
[TBL] [Abstract][Full Text] [Related]
31. Pathobiological implications of mucin (MUC) expression in the outcome of small bowel cancer.
Shibahara H; Higashi M; Koriyama C; Yokoyama S; Kitazono I; Kurumiya Y; Narita M; Kuze S; Kyokane T; Mita S; Arai T; Kato T; Yuasa N; Yamaguchi R; Kubota H; Suzuki H; Baba S; Rousseau K; Batra SK; Yonezawa S
PLoS One; 2014; 9(4):e86111. PubMed ID: 24722639
[TBL] [Abstract][Full Text] [Related]
32. Diagnosis of pancreatic neoplasms using a novel method of DNA methylation analysis of mucin expression in pancreatic juice.
Yokoyama S; Kitamoto S; Higashi M; Goto Y; Hara T; Ikebe D; Yamaguchi T; Arisaka Y; Niihara T; Nishimata H; Tanaka S; Takaori K; Batra SK; Yonezawa S
PLoS One; 2014; 9(4):e93760. PubMed ID: 24714692
[TBL] [Abstract][Full Text] [Related]
33. Reevaluation and identification of the best immunohistochemical panel (pVHL, Maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas.
Liu H; Shi J; Anandan V; Wang HL; Diehl D; Blansfield J; Gerhard G; Lin F
Arch Pathol Lab Med; 2012 Jun; 136(6):601-9. PubMed ID: 22646265
[TBL] [Abstract][Full Text] [Related]
34. The expression of MUC mucin in cholangiocarcinoma.
Mall AS; Tyler MG; Ho SB; Krige JE; Kahn D; Spearman W; Myer L; Govender D
Pathol Res Pract; 2010 Dec; 206(12):805-9. PubMed ID: 20947262
[TBL] [Abstract][Full Text] [Related]
35. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
[TBL] [Abstract][Full Text] [Related]
36. Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact.
Park SY; Roh SJ; Kim YN; Kim SZ; Park HS; Jang KY; Chung MJ; Kang MJ; Lee DG; Moon WS
Oncol Rep; 2009 Sep; 22(3):649-57. PubMed ID: 19639217
[TBL] [Abstract][Full Text] [Related]
37. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression.
Reis CA; David L; Correa P; Carneiro F; de Bolós C; Garcia E; Mandel U; Clausen H; Sobrinho-Simões M
Cancer Res; 1999 Mar; 59(5):1003-7. PubMed ID: 10070955
[TBL] [Abstract][Full Text] [Related]
38. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
[TBL] [Abstract][Full Text] [Related]
39. Mucinous phenotype and CD10 expression of primary adenocarcinoma of the small intestine.
Kumagai R; Kohashi K; Takahashi S; Yamamoto H; Hirahashi M; Taguchi K; Nishiyama K; Oda Y
World J Gastroenterol; 2015 Mar; 21(9):2700-10. PubMed ID: 25759539
[TBL] [Abstract][Full Text] [Related]
40. MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer.
Cozzi PJ; Wang J; Delprado W; Perkins AC; Allen BJ; Russell PJ; Li Y
Clin Exp Metastasis; 2005; 22(7):565-73. PubMed ID: 16475027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
